Becton Dickinson & Co Stock Price, News & Analysis

BD (Becton, Dickinson and Company) announced a significant advancement in flow cytometry through its new BD CellView™ Image Technology, highlighted in the journal Science. This technology allows for the sorting of individual cells at speeds of up to 15,000 cells per second, integrating fluorescence imaging for enhanced analysis. The system captures detailed images, enabling precise identification of biomarkers and their distributions, which could accelerate research in immunology and genomics. The technology promises to transform cell-based therapeutic discovery, filling long-standing gaps in biomedical research.

BD (Becton, Dickinson and Company) announces a collaboration with Pfizer and Wellcome to enhance antimicrobial stewardship through improved diagnostic practices. This initiative aims to identify gaps in current diagnostic testing related to antimicrobial resistance (AMR), which poses a significant global health challenge, potentially leading to 10 million deaths annually by 2050. Experts emphasize the need for better diagnostic tools and education to combat AMR effectively. The COVID-19 pandemic has highlighted the importance of diagnostics in managing antibiotic use.

BD (Becton, Dickinson and Company) has received FDA 510(k) clearance for its BD Kiestra™ IdentifA system, aimed at automating microbiology bacterial identification testing. This automated system utilizes BD Synapsys™ informatics and robotics to enhance accuracy and efficiency, reducing human error in sample preparation. The BD Kiestra™ IdentifA is notable for being the only FDA-cleared solution integrated into a track-connected lab automation system. This innovation seeks to improve patient management by accelerating pathogen identification, thereby supporting better clinical decision-making.

BD (Becton, Dickinson and Company) has announced that its 2022 Annual Meeting of Shareholders will be held virtually on January 25, 2022, at 1:00 p.m. EST, due to health concerns related to the COVID-19 pandemic. Shareholders of record as of December 6, 2021, can participate in the meeting. Various registration options are available for both registered and street holders of shares. BD encourages shareholders to vote and submit proxies in advance.

BD (Becton, Dickinson and Company) has released its 2021 Cybersecurity Annual Report to inform stakeholders about health care cybersecurity challenges and trends. The report highlights key issues, including cybersecurity risks like phishing and ransomware, and emphasizes the need for collaboration in enhancing security measures across the industry. It introduces best practices for health care providers and outlines upcoming trends such as software-bill-of-materials (SBOM) requirements for 2022. BD aims to integrate cybersecurity throughout its product lifecycle for improved patient care.

BD (Becton, Dickinson and Company) (NYSE: BDX) will release its financial results for Q1 of fiscal year 2022 on February 3, 2022, at 6 a.m. ET. The announcement will include summary financial data for the quarter ending December 31, 2021. Following the release, management will host an audio webcast at 8 a.m. ET to discuss results and operational strategies. For further details and the live audio link, visit www.bd.com/investors. BD is committed to advancing healthcare through innovative technology and solutions.

BD (Becton, Dickinson and Company) (NYSE: BDX), a prominent medical technology leader, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 2:15 p.m. Eastern Time. The presentation will be accessible via live webcast on BD's investor relations website, with a replay available afterward. BD focuses on advancing health through technology, diagnostics, and care delivery, supporting healthcare providers and enhancing patient outcomes globally.

BD (Becton, Dickinson and Company) has launched the BD Veritor™ At-Home COVID-19 Test, now available through Everly Health and Southeastern Grocers, including Fresco y Más, Harveys Supermarket, and Winn-Dixie. The test is unique as it utilizes a smartphone app to interpret results, ensuring accuracy without human error. BD emphasizes the test's importance for community safety amidst rising COVID-19 cases, especially during the holiday season. The test is available online and in-store, enabling broad access for consumers.